Serina Therapeutics, Inc.
SER evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $56.4M
- Lead Asset:
- ser 214 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for SER—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SER
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates for neurological diseases and other indications, leveraging its proprietary POZ Platform™ drug delivery technology [sec · filed 2026-08-24].
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 4 of 6 signals
Market Cap
$56.4M
Cash Runway
—
Lead Asset
ser 214 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Serina Therapeutics, Inc..
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates for neurological diseases and other indications, leveraging its proprietary POZ Platform™ drug delivery technology [sec · filed 2026-08-24].
- Clinical-stage biotechnology company developing wholly-owned drug product candidates for neurological diseases and other indications using its POZ Platform™ drug delivery technology [sec · filed 2026-08-24].
- Lead product candidate SER-252 is in a Phase 1b registrational study for advanced Parkinson's disease; enrollment and dosing in Cohort 1 completed as of August 2026 [news · published 2026-08-13].
- Cash and equivalents of $23.0M as of 2026-06-30 [sec]; net income of -$6.4M for the same period [sec].
- Closed a $21.2 million private placement financing in Q1 2026 to support SER-252 development [news · published 2026-05-14].
- FDA granted IND clearance for SER-252 in early 2026, enabling the Phase 1b trial initiation [news · published 2026-03-25].
What works
- Proprietary POZ Platform™ drug delivery technology enables modification of existing drugs and novel candidates, providing a potential competitive advantage in drug optimization [sec · filed 2026-08-24].
- Lead candidate SER-252 has advanced to a Phase 1b registrational study with FDA IND clearance, indicating regulatory progress [news · published 2026-08-13].
- Company secured $21.2 million in private placement financing in early 2026, demonstrating investor support for its pipeline [news · published 2026-05-14].
What to weigh
- Company has no revenue ($0.0M as of 2026-06-30) and continues to incur net losses (net income -$6.4M for the same period) [sec].
- Cash and equivalents of $23.0M as of 2026-06-30 may be insufficient to fund all planned activities; the company expects to need additional financing and may need to delay, reduce, or terminate activities to reduce costs [sec_mda · as of 2026-08-13].
- Net losses are expected to continue for the foreseeable future, with expenses increasing as clinical trials and regulatory activities progress [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Company is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.
“We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.”
SEC filings · August 24, 2026
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252.
“Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252”
News · August 13, 2026
Company expects to continue to incur net losses for the foreseeable future.
“We expect to continue to incur net losses for the foreseeable future”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Company has $0.0M revenue and net loss of -$6.4M as of 2026-06-30 [sec]; expects continued net losses [sec_mda · as of 2026-08-13].
- Cash runway uncertainty — $23.0M cash as of 2026-06-30 may not cover all planned activities; may need to delay or terminate programs [sec_mda · as of 2026-08-13].
- Clinical trial execution risk — Phase 1b registrational study of SER-252 is early-stage; top-line data not expected until first half of 2027 [news · published 2026-08-13].
- Dependence on additional financing — Company states it will require additional financing to continue development [sec_mda · as of 2026-08-13].
What to watch
- Top-line data from the single-ascending-dose arm of SER-252 Phase 1b study, targeted for first half of 2027 [news · published 2026-08-13].
- Cash position and burn rate updates in future quarterly filings to assess runway [sec_mda · as of 2026-08-13].
- Progress of IND-enabling studies and potential future clinical trials for SER-252 and other product candidates [sec_mda · as of 2026-08-13].
- Ability to secure additional financing to support ongoing development [sec_mda · as of 2026-08-13].
Sources: News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Serina Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Serina Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$6M
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
7 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$2.8M
| Holder | Shares | Value |
|---|---|---|
| sio capital management, llc | 1,000,000 | $1.9M |
| vanguard capital management llc | 159,136 | $309K |
| waverly advisors, llc | 67,492 | $131K |
| geode capital management, llc | 64,973 | $126K |
| blackrock, inc. | 58,264 | $113K |
| jane street group, llc | 39,653 | $77K |
| vanguard fiduciary trust co | 20,009 | $39K |
| avidian wealth enterprises, llc | 18,800 | $36K |
| state street corp | 12,758 | $25K |
| caitong international asset management co., ltd | 3,982 | $8K |
Showing top 10 of 24 institutional holders of Serina Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 7.1%
- Days to cover
- 0.1
- Shares short
- 478,077
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SER short interestGovernance
Frequently asked questions
What is the AI investment thesis for Serina Therapeutics, Inc.?
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates for neurological diseases and other indications, leveraging its proprietary POZ Platform™ drug delivery technology [sec · filed 2026-08-24].
What is Serina Therapeutics, Inc.'s lead drug candidate?
Serina Therapeutics, Inc.'s most advanced tracked candidate is ser 214 (Phase 1) for early Parkinson's disease and Restless Leg Syndrome.
Who is the CEO of Serina Therapeutics, Inc.?
Mr. Steven A. Ledger is the chief executive officer of Serina Therapeutics, Inc. (SER).
Where is Serina Therapeutics, Inc. headquartered?
Serina Therapeutics, Inc. (SER) is headquartered in Huntsville, AL, United States.
What therapeutic areas does Serina Therapeutics, Inc. focus on?
Serina Therapeutics, Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.